Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 3, 2001, Pages 806-810

  Anderson, Mark E ^a   Mazur, Alexander ^b   Yang, Tao ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; GREPAFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DRUG POTENCY; HEART ATRIUM; HEART PROARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; MOUSE; NONHUMAN; POTASSIUM CURRENT; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RABBIT; TORSADE DES POINTES; VOLTAGE CLAMP;

4-QUINOLONES; ANIMALS; ANTI-INFECTIVE AGENTS; ARRHYTHMIA; AZA COMPOUNDS; CATION TRANSPORT PROTEINS; DNA-BINDING PROTEINS; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOROQUINOLONES; LONG QT SYNDROME; MICE; MODELS, ANIMAL; PATCH-CLAMP TECHNIQUES; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; QUINOLINES; RABBITS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0035123579     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers
2. In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates
3. Prolonged action potential duration and positive inotropy induced by the novel class III antiarrhythmic agent H 234/09 (Almokalant) in isolated human ventricular muscle
4. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion and early afterdepolarisations
5. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization
6. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions
7. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
8. Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits
9. A structural basis for drug-induced long QT syndrome
10. Mechanisms and management of proarrhythmia
11. Taking the "idio" out of "idiosyncratic": Predicting torsades de pointes
12. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS
13. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin
14. Kr. Implications for torsade de pointes and reverse use-dependence
15. + channel mRNA in cultured atrial cardiac myocytes (AT-1 cells)